Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis

References

• The cancer of the liver Italian program. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the cancer of the liver Italian program (CLIP) investigators. Hepatology. 1998;28(3):751–755. doi:10.1002/hep.510280322
   PubMed Web of Science ®Google Scholar
• Xu XL, Liu XD, Liang M, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology. 2018;287:461–472. doi:10.1148/radiol.2017162756
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156:477–491.e471. doi:10.1053/j.gastro.2018.08.065
   PubMed Web of Science ®Google Scholar
• Ko KL, Mak LY, Cheung KS, et al. Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Res. 2020;9:620. doi:10.12688/f1000research.24543.1
   Google Scholar
• Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer. 2011;117:4475–4483. doi:10.1002/cncr.25960
   PubMed Web of Science ®Google Scholar
• Natsuizaka M, Omura T, Akaike T, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol. 2005;20:1781–1787. doi:10.1111/j.1440-1746.2005.03919.x
   PubMed Web of Science ®Google Scholar
• Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A Phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41:117–127. doi:10.1200/jco.22.00392
   PubMed Web of Science ®Google Scholar
• Lee HS. Management of patients with hepatocellular carcinoma and extrahepatic metastasis. Dig Dis. 2011;29:333–338. doi:10.1159/000327572
   PubMed Web of Science ®Google Scholar
• Beckham TH, Yang TJ, Gomez D, et al. Metastasis-directed therapy for oligometastasis and beyond. Br J Cancer. 2021;124:136–141. doi:10.1038/s41416-020-01128-5
   PubMed Web of Science ®Google Scholar
• Hsu CY, Liu PH, Ho SY, et al. Metastasis in patients with hepatocellular carcinoma: prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system. Liver Int. 2018;38:1803–1811. doi:10.1111/liv.13748
   PubMed Web of Science ®Google Scholar
• Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut. 2021;70:204–214. doi:10.1136/gutjnl-2020-321702
   PubMed Web of Science ®Google Scholar
• Wong AC, Watson SP, Pitroda SP, et al. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016;122:2242–2250. doi:10.1002/cncr.30058
   PubMed Web of Science ®Google Scholar
• Salama JK, Milano MT. Radical irradiation of extracranial oligometastases. J Clin Oncol. 2014;32:2902–2912. doi:10.1200/JCO.2014.55.9567
   PubMed Web of Science ®Google Scholar
• Feng Z, Rong P, Wang W. Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma. Gut. 2020;69:1904–1906. doi:10.1136/gutjnl-2019-320116
   PubMed Web of Science ®Google Scholar
• Liu Z, Lin Y, Zhang J, et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Experim Clin Can Res. 2019;38:447. doi:10.1186/s13046-019-1412-8
   PubMed Web of Science ®Google Scholar
• Zhu XD, Sun HC. Emerging agents and regimens for hepatocellular carcinoma. J Hematol Oncol. 2019;12:110. doi:10.1186/s13045-019-0794-6
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38:2960–2970. doi:10.1200/jco.20.00808
   PubMed Web of Science ®Google Scholar
• Bedrose S, Miller KC, Altameemi L, et al. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. J ImmunoTher Can. 2020;8:e001009. doi:10.1136/jitc-2020-001009
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang M, Zhu J, et al. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomed Pharmacothe. 2020;132:110797. doi:10.1016/j.biopha.2020.110797
   PubMed Web of Science ®Google Scholar
• World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194. doi:10.1001/jama.2013.281053
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Michitaka K, et al. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer. 2019;8:312–325. doi:10.1159/000494844
   PubMed Web of Science ®Google Scholar
• Lu J, Zhang XP, Zhong BY, et al. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol. 2019;4:721–730. doi:10.1016/S2468-1253(19)30178-5
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, Phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6:559–568. doi:10.1016/S2468-1253(21)00109-6
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kudo M, Merle P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1399–1410. doi:10.1016/S1470-2045(23)00469-2
   PubMed Web of Science ®Google Scholar
• Li Q, Cao M, Yuan G, et al. Lenvatinib plus camrelizumab vs. lenvatinib monotherapy as first-line treatment for unresectable hepatocellular carcinoma: A multicenter retrospective cohort study. Front Oncol. 2022;12:809709. doi:10.3389/fonc.2022.809709
   PubMed Web of Science ®Google Scholar
• Gunda V, Gigliotti B, Ashry T, et al. Anti-PD-1/PD-L1 therapy augments lenvatinib’s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer. Int j Canc. 2019;144:2266–2278. doi:10.1002/ijc.32041
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label Phase 2 trial. Lancet Oncol. 2018;19:940–952. doi:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502. doi:10.1016/s0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Takahashi K, Kim J, Takahashi A, et al. Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: a case report. World j hepato. 2021;13:384–392. doi:10.4254/wjh.v13.i3.384
   PubMed Web of Science ®Google Scholar
• Luo F, Li M, Ding J, et al. The progress in the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Front Oncol. 2021;11:635731. doi:10.3389/fonc.2021.635731
   PubMedGoogle Scholar
• Mukozu T, Nagai H, Matsui D, et al. Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis. Canc Chemother Pharm. 2022;89:11–20. doi:10.1007/s00280-021-04359-2
   PubMed Web of Science ®Google Scholar
• Chuma M, Uojima H, Hiraoka A, et al. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: a multicenter analysis. Hepat rese. 2021;51:201–215. doi:10.1111/hepr.13592
   Google Scholar
• Kuzuya T, Ishigami M, Ito T, et al. Sorafenib vs. lenvatinib as first-line therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Anticanc Res. 2020;40:2283–2290. doi:10.21873/anticanres.14193
   PubMed Web of Science ®Google Scholar
• Kaneko S, Tsuchiya K, Yasui Y, et al. Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. Hepat rese. 2020;50:1375–1385. doi:10.1111/hepr.13567
   Google Scholar
• Yan B, Bai DS, Zhang C, et al. Characteristics and risk differences of different tumor sizes on distant metastases of hepatocellular carcinoma: a retrospective cohort study in the SEER database. Int j Surg. 2020;80:94–100. doi:10.1016/j.ijsu.2020.06.018
   PubMed Web of Science ®Google Scholar
• Mokdad AA, Singal AG, Marrero JA, et al. Vascular Invasion and Metastasis is Predictive of Outcome in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. J Natiol Compreh Canc Net. 2017;15:197–204. doi:10.6004/jnccn.2017.0020
   PubMed Web of Science ®Google Scholar